gerkorean.blogg.se - Microsoft edge icon color branding

Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Comparison based on publicly available information. Data on file, Abbott Diabetes Care.Ĥ Data on file, Abbott Diabetes Care. Excluding specified items, Abbott is raising its projected adjusted diluted earnings per share to $5.17 to $5.23 for the full-year 2022.Ģ All reported amounts relate to continuing operations only as there are no discontinued operations in the periods presented.ģ Among patient-applied sensors. Abbott forecasts specified items for the full-year 2022 of $1.42 per share primarily related to intangible amortization, costs related to a voluntary recall, asset impairments, expenses associated with acquisitions, restructurings and cost reduction initiatives and other net expenses. *Organic sales growth excludes the impact of foreign exchange.ġ Abbott is raising its projected full-year 2022 diluted earnings per share under GAAP to $3.75 to $3.81.

Food and Drug Administration Emergency Use Authorization for Monkeypox PCR test used with the Alinity m system.įor full financials and reconciliation of non-GAAP measures, you can read Abbott's press release.įor further information, take a look at a summary of Abbott’s earnings highlights and download it here.

New data showing the FreeStyle Libre continuous glucose monitoring system reduces diabetes-related hospitalizations for people with Type 2 diabetes on once-daily insulin therapy.

launch of the FreeStyle Libre 3 system, which automatically delivers up-to-the-minute glucose readings and unsurpassed 14-day accuracy 3 in the world's smallest and thinnest 3 wearable sensor.

Medical Devices business, which reported strong, double-digit growth in Electrophysiology, Structural Heart and Diabetes Care.Ībbott continues to strengthen its portfolio with regulatory approvals, real-world data and new product introductions, including: The company's results were led by strong performance in Established Pharmaceuticals and the U.S.

$1.7 billion in global COVID-19 testing-related sales.Ībbott's diversified business model has been driving the company's success and setting it apart from competitors for more than 130 years.

$10.4 billion in worldwide sales, increasing 1.3% organic* (decreasing 4.7% reported).

On a reported basis, diluted EPS was $0.81.

$1.15 in adjusted diluted EPS, which excludes specified items.

Abbott continued leaning into its diverse business portfolio during the third quarter's volatile market and significantly exceeded Street estimates.īased on the company's strong performance so far this year, Abbott is raising its full-year 2022 projected adjusted diluted earnings per share (EPS) guidance to $5.17 to $5.23.